Surgery Partners’ planned sale of Mountain View Hospital and Idaho Falls Community Hospital would bring in about $586.5 million in net cash at closing, after estimated closing cash and indebtedness of $219.7 million, working-capital adjustments of $9.6 million and transaction costs.
On a pro forma basis as of June 30, 2026, cash and cash equivalents would rise to $708.8 million from $216.7 million, an increase of $492.1 million. Total current assets would climb to $1.42 billion from $1.13 billion.
The transaction would shrink several balance-sheet items tied to the divested business. Accounts receivable would fall to $466.5 million from $616.6 million, inventories to $74.7 million from $98.8 million, and other current assets to $171.6 million from $193.9 million. Property and equipment, net would drop to $838.5 million from $1.12 billion, while goodwill and intangible assets, net would decline to $4.65 billion from $5.24 billion.
Total assets would decrease to $7.41 billion from $8.05 billion.
On the liability side, accounts payable would decline to $132.9 million from $175.2 million, other current liabilities to $253.7 million from $300.4 million, and current maturities of long-term debt to $70.4 million from $102.9 million. Long-term debt, less current maturities, would fall to $3.33 billion from $3.65 billion. Total current liabilities would drop to $457.0 million from $578.5 million, and total liabilities would fall to $4.47 billion from $4.95 billion.
Equity would move to $2.94 billion from $3.10 billion. Retained deficit would improve to $(844.8) million from $(866.1) million, and non-controlling interests — non-redeemable would decrease to $1.25 billion from $1.43 billion.
For the six months ended June 30, 2026, pro forma revenue would have been $1.29 billion, down from $1.66 billion reported. Cost of revenues would have fallen to $1.00 billion from $1.31 billion. Operating income would have been $127.8 million, down from $167.9 million. Income before taxes would nearly disappear at $0.1 million, versus $29.0 million reported. Net income attributable to Surgery Partners would have been a loss of $69.2 million, compared with a loss of $50.9 million.
Net loss per share attributable to common stockholders would have widened to $0.54 from $0.40.
For full-year 2025, pro forma revenue would have been $2.59 billion, down from $3.31 billion. Cost of revenues would have been $1.96 billion, compared with $2.54 billion. Operating income would have been $314.8 million, down from $389.5 million. Income before taxes would have been $67.5 million, versus $116.9 million. Net income attributable to Surgery Partners would have been a loss of $108.2 million, compared with a loss of $77.9 million.
Net loss per share would have widened to $0.85 from $0.61. As a result of these announcements, the company's shares have moved -2.88% on the market, and are now trading at a price of $13.5295. If you want to know more, read the company's complete 8-K report here.
